Common Psoriasis Treatments May Reduce Coronary Plaque

Biologic treatments commonly used for the treatment of psoriasis may also help reduce atherosclerotic plaque volume (PV), according to a new study.

These findings may have implications for future treatment efforts, since psoriasis is known to be associated with increased risks of myocardial infarction and atherogenesis, the authors of the study said.
_______________________________________________________________________________

RELATED CONTENT
FDA Approves New Psoriasis Drug
Could Psoriasis and Eczema Be Treated With Cannabis?
_______________________________________________________________________________

In their study, Nehal N. Mehta, MD MSCE FAHA, the principal investigator of the study from the National Heart, Lung, and Blood Institute, and colleagues assessed 80 patients with psoriasis. Of these patients, 57 used biologic treatment (predominantly anti-tumor necrosis factor [anti-TNF] agents) and 27 used non-biologic treatment.

Coronary computed tomography (CT) angiography was used to assess non-calcified burden, PV, and maximal artery stenosis in the proximal vessels.

Results of the study, which were discussed at the Society for Cardiovascular Angiography and Interventions’ 2018 Scientific Sessions, indicated that PV among biologic-treated patients had decreased by 40% after 1 year.

The researchers noted that change in PV was also positively associated with a change in the proinflammatory cytokine interleukin-1 beta. This association remained significant even after adjustment for various factors.

“To see a reduction in coronary plaque after just one year of biologic therapy alone is incredible and very assuring,” said Dr Mehta in a press release. “It's the first time we're seeing treatment of a skin disease with biologic therapy have an impact specifically on plaque in the coronary.”

—Christina Vogt

Reference:

Abu-Fadel MS, Brinton TJ, Hodgson JM, et al. Immunomodulatory therapy reduces atherosclerotic plaque burden by coronary computed tomography angiography in psoriasis at one year. Presented at: SCAI 2018 Scientific Sessions; April 25-28, 2018; San Diego, CA.

SEE ALSO: Psoriasis, Diabetes, and Other Comorbidities (Podcast)

Dr Joel Gelfand, a professor of dermatology at the University of Pennsylvania Perelman School of Medicine, discusses his latest research on the interaction between psoriasis and diabetes, as well as other comorbidities.

For more podcasts, click here.